Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 9Stomach Neoplasms 6Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Solid Tumor 3Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Muscle Invasive Bladder Cancer 1

Interventions

pembrolizumab 16Carboplatin 10Paclitaxel 8Nivolumab 7Bevacizumab 6Gemcitabine 4Fulvestrant 4Cisplatin 4olaparib 3lenvatinib 3abemaciclib 3PM 01183 3Oxaliplatin 3Leucovorin 3Letrozole 3Docetaxel 3AZD5305 3tisotumab vedotin 2spartalizumab 2sarilumab 2sargramostim 2sacituzumab govitecan 2ribociclib 2palbociclib 2epacadostat 2enzalutamide 2dostarlimab 2cemiplimab 2anlotinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Endometrial Neoplasms × tislelizumab × Clear all
NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
52 enrolled 23 charts
BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡